A c c e p t e d M a n u s c r i p t
Introduction
Neurosurgical critically ill patients frequently require placement of an external central nervous system (CNS) catheter for drainage of cerebrospinal fluid (CSF) to better control intracranial pressure. It is estimated that 1-2% of patients admitted to an intensive care unit (ICU) have an intraventricular catheter in situ [1] . These devices are frequently manipulated to ensure optimal function and, whilst strict aseptic methods are targeted for use [2] , CNS infections are common in these patients. The frequency of CNS infections resulting from neurosurgical procedures is estimated to be ca. 4% [3] , and Gram-positive cocci, mainly Staphylococcus spp., are the most common causative pathogens [4] .
Linezolid is considered to be a useful treatment option for CNS infections, particularly where mediated by resistant Gram-positive bacteria [5] [6] [7] . Linezolid has good antibacterial activity against these micro-organisms, including meticillin-resistant Staphylococcus aureus (MRSA), coagulase-negative staphylococci (e.g. Staphylococcus epidermidis) and vancomycin-resistant enterococci [8] . Over the last few years, several studies have become available that support the efficacy and safety of linezolid in the treatment of CNS infections [3, 9, 10] . Linezolid has been reported to have a favourable pharmacokinetic (PK) profile, achieving high concentrations in CSF and showing a penetration ratio for the area under the drug concentration-time curve (AUC) for CSF to the AUC for serum close to 1 [11] . Some PK studies have been performed in animal models, healthy volunteers or non-critically ill patients [12] [13] [14] . Studies evaluating penetration of linezolid into the CNS in critically ill patients have shown widely variable results
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A c c e p t e d M a n u s c r i p t [4, [12] [13] [14] [15] [16] . This population can develop severe pathophysiological changes (e.g.
hyperdynamic state, need for vasopressor drugs, augmented or impaired renal function) that can alter the pharmacokinetics of many antimicrobials leading to decreased effectiveness [17] . Such PK changes may affect antibiotic penetration into the CSF and cause wide interindividual variability in CSF concentrations.
In human studies, the time the plasma linezolid concentration exceeds the minimum inhibitory concentration (T >MIC ) and the ratio of AUC from time 0 to 24 h to MIC (AUC 0-24h /MIC) have been related to bacteriological and clinical outcomes. In seriously ill patients, higher efficacy rates were observed when the T >MIC was 85%
and the AUC 0-24h /MIC was in the range of 80-120 [18, 19] . When considering an MIC of 2 mg/L, optimal pharmacokinetic/pharmacodynamic (PK/PD) targets in plasma and CSF were achieved in the majority of the previously described experiences [12] [13] [14] [15] . However, using an MIC of 4 mg/L, a value for less susceptible strains [20] , these PK/PD ratios were only achieved in two studies [12, 15] .
To the best of our knowledge, a population PK study of linezolid concentrations in plasma and CSF in critically ill patients with ventricular drains in situ is yet to be performed. Such an analysis could help better describe this interindividual variability and its implications for linezolid dosing in these patients. Given the lack of PK certainty of linezolid penetration into the CSF and the achievement of pharmacodynamic targets, the objective of this study was to describe the population pharmacokinetics of linezolid in plasma and CSF in critically ill patients with external CNS drainage and proven or suspected CNS infections.
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A c c e p t e d M a n u s c r i p t For patients with normal baseline values, anaemia was defined as a reduction in haemoglobin in the range of 8-10 g/dL or less, and thrombocytopenia was defined as a platelet count <75 000 cells/mm 3 unexplained by any other causes.
Materials and methods

Study design and population
The presence of oedema was evaluated on the basis of physical examination by the responsible clinician.
Plasma and cerebrospinal fluid sample collection
Plasma and CSF sampling occurred after 3 days of treatment. Blood samples (4 mL)
were collected just before initiation of the linezolid infusion (trough in plasma; C min,ss ) and at 1 h (peak in plasma; C max,ss ) in four patients and also at 3, 5, 8 and 12 h thereafter in seven patients. CSF samples (1 mL) were collected simultaneously with each blood sample. Blood and CSF samples were collected in heparinised tubes, immediately centrifuged (3000 g for 10 min at 4 C) and the plasma was stored at -80 C until analysis.
Bioanalysis
Linezolid concentrations were determined using a validated high-performance liquid 
Population pharmacokinetic analysis
The concentration-time data for linezolid in plasma and CSF were fitted using nonlinear mixed-effects modelling (NONMEM v.7.2; Globo Max LLC, Hanover, MD) [22] .
A Digital Fortran compiler was used and the runs were executed using Wings for NONMEM (http://wfn.sourceforge.net). Data were analysed using the first-order 
Population pharmacokinetic model diagnostics
Visual inspection of diagnostic scatter plots and the NONMEM OFV were used to evaluate goodness of fit. Statistical comparison of nested models was undertaken in the NONMEM program using log-likelihood ratios, which are assumed to be 2 distributed. On the basis of a 2 test of the difference in OFV, a decrease in the OFV of 3.84 units (P < 0.05) for one degree of freedom was considered statistically significant. Decreases in BSV of one of the parameters of at least 10% were also accepted for inclusion of a more complicated model.
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Population pharmacokinetic covariate screening
Covariate model building was performed in a stepwise fashion with forward inclusion and backward deletion based upon the aforementioned model selection criteria. Age, sex, weight, serum creatinine concentration, APACHE II score and use of vasopressors were evaluated as covariates.
Population pharmacokinetic bootstrap
A non-parametric bootstrap method (n = 1000) was used to study the uncertainty of the PK parameter estimates in the final model. From the bootstrap empirical posterior distribution, we have been able to obtain the 95% confidence interval (CI)
for the parameters, as described previously [23] .
Other pharmacokinetic calculations
The maximum (C max ) and minimum (C min ) concentration in plasma and CSF for the dosing interval were the observed values. The AUC from 0 to 12 h (AUC 0-12h ) was calculated using the trapezoidal rule. AUC 0-24h was calculated as AUC 0-12h 2.
Penetration of linezolid into the CSF was described using the CSF/plasma ratio, which was calculated by dividing the CSF AUC 0-12h by the plasma AUC 0-12h .
Assessment of pharmacodynamics and efficacy thresholds
An AUC 0-24h /MIC ratio of 80-120 was considered the optimal target for efficacy because this threshold has been related to higher clinical success and bacteriological rates [19, 24] . 
Results
Eleven patients were included in the study and 46 blood samples and 45 CSF samples were collected. The demographic and clinical characteristics of the patients are detailed in Table 1 . The mean patient age was 51.9 ± 10.3 years and 7 (63.6%)
were male. The most frequent neurological disease was subarachnoid haemorrhage, observed in 7 (63.6%) of the patients. Ten patients (90.9%) were CSF-culture negative and one patient (9.1%) cultured S. epidermidis that was susceptible to linezolid. The mean treatment duration with linezolid was 9.5 ± 6.2 days. No patient had a GFR < 80 mL/min on the day of sampling. Table 2 .
Linezolid was well tolerated by all patients, with no adverse effects observed in any of the patients.
Pharmacokinetic model building
Eight patients were used to build the model as three patients did not have sufficient data points (more than two plasma and CSF samples) to meet the a priori model- Table 3 . The goodness of fit plots are shown in Fig. 3 . After screening all relevant biologically plausible covariates, none were found to statistically significantly improve the model so could not be included in the final model.
Discussion
To the best of our knowledge, this is the first population PK study of linezolid in plasma and CSF in critically ill neurological patients with proven or suspected CNS infection caused by Gram-positive micro-organisms. It is also the largest study of its type with linezolid. The results showed a moderate-to-good overall penetration of linezolid into the CSF, with a median AUC 0-12h CSF/plasma ratio of 0.77. Despite this, a wide variability between patients was observed in the plasma and CSF concentrations and CSF/plasma ratios. This variability is most likely due to the range of sickness severity of the included patients and the consequent effect that the associated altered physiology has on linezolid disposition. These findings, which agree with those from previous studies that have also described large interindividual variability in the concentrations of linezolid in plasma [21] and CSF [12] , support the need for therapeutic drug monitoring (TDM) of linezolid in plasma and also potentially in CSF to avoid treatment failures due to underexposure [21] . The strong positive correlation observed between the C min,ss of linezolid in plasma and the concentration in CSF suggests that plasma concentrations could be used as predictors of CSF concentrations if only trough concentration (as opposed to AUC 0-24h ) monitoring was available.
Variable results have been published on whether plasma linezolid concentrations can be used as a surrogate of CSF concentrations. In one case study of linezolid in meningitis, the authors reported similar drug concentrations in plasma and CSF and suggested that plasma concentrations are a suitable indicator of CSF penetration [15] . This is unsurprising as drug penetration in meningitis should be greater than in patients with non-inflamed meninges. Similar to this case study, other authors also described positive correlations between the C max,ss of linezolid in plasma and in CSF [12] . However, other investigators have not found such correlations between in plasma and CSF concentrations of linezolid [16] . In our patients, although significant correlation between plasma and CSF concentrations was seen for trough concentrations, significant other correlations were not observed. The variable CSF/plasma AUC ratios seen in this study suggest that consistent correlations are generally unlikely with this drug.
In this study, the linezolid concentrations in plasma and CSF were much lower than those reported in most other PK studies performed in critically ill patients [12] [13] [14] [15] 25] .
The population PK model that best described the data was a three-compartment linear model. The mean volume of distribution of linezolid (101.3 L) estimated in this study was much higher than that reported in previous studies in the same patient group (42.8 L or 40.1 L) [13, 14] . Our volume of distribution estimates are more in line with those from another critically ill patient PK study [26] . In contrast, the estimated linezolid clearance (16.6 L/h) was found to be much higher (7.3 L/h or 7.9 L/h) [12, 13] , a fact probably explained by the better apparent renal function of our patients compared with those included in the previous studies. The estimated A c c e p t e d M a n u s c r i p t clearance values described in this study more closely align with the estimates from a sepsis cohort reported by Plock et al. [27] . A c c e p t e d M a n u s c r i p t higher) [13] ; the mean CSF C max,ss and C min,ss were 7.1 mg/L (222% higher) and 3.1 mg/L (620% higher) [13] .
One likely explanation for the lower exposures of linezolid observed in our patients is the conserved renal function of our patients. In particular, the mean calculated creatinine clearance (CL Cr ) estimates of our patients were much higher than those reported in the Myrianthefs et al. study (151 mL/min compared with 81 mL/min) [12] .
A correlation between a low C min,ss of linezolid in plasma and increasing calculated CL Cr has been shown previously [28] . In a recent study of 78 patients with acute infections, a value of calculated CL Cr > 80 mL/min was identified as a risk factor for achieving a linezolid C min < 2 mg/L in plasma (odds ratio = 10; 95% CI 2.732-37.037; P = 0.001) [28] . However, this association was not observed in the current study, where linezolid levels in plasma and CSF were not correlated with patients' renal function, probably due to the comparatively smaller sample size. This phenomenon of augmented renal clearance (ARC) and its association with increased antibiotic clearance and decreased concentrations has been previously shown for -lactams [29] . In our patients, ARC is likely and would be caused by the pathophysiological response to the CNS pathology, including increased renal blood flow [30] . The effects of ARC on linezolid pharmacokinetics has not been previously described, although direct causality cannot be shown here as measured CL Cr data were not available and neither were urine concentration data. One limitation of this study is the fact that CL Cr of patients was estimated because the measurement is not routinely performed in Hospital del Mar.
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Regarding toxicity, administration of linezolid at standard dosages was not associated with any haematological toxicity, although prolonged durations of therapy were not required in this study.
In conclusion, this is the largest PK study of critically ill patients with proven or M a n u s c r i p t A c c e p t e d M a n u s c r i p t Table 2 Individual A c c e p t e d M a n u s c r i p t 
